Objective: To study the clinical efficacy and possible mechanism of Xuanfei Jiangzhuo Recipe in the treatment of con-stipation irritable bowel syndrome (IBS-C). Methods: 120 patients were randomly divided into two groups: 60 cases in the treatment group were treated with Xuanfei Jiangzhuo Recipe and 60 cases in the control group with Cisapride. The clinical symptoms, quality of life and recurrence after treatment were recorded. The levels of neuropeptide Y (NPY), 5-hydroxytryptamine (5-HT), vasoactive in-testinal peptide (VIP) and calcitonin gene-related peptide (CGRP) were measured. Results: The clinical symptom score, total effec-tive rate, score of life quality and recurrence rate of the treatment group were better than those of the control group, and the difference was significant ( P <0.05). Compared with the group before treatment, 5-HT, NPY, VIP and CGRP decreased significantly after treatment ( P <0.05). Compared with the control group after treatment, 5-HT, VIP and NPY levels in the treatment group decreased significantly ( P <0.05), while the CGRP level increased, but the difference was not significant ( P >0.05). Conclusion: Xuanfei Jiangzhuo Recipe can not only improve the clinical symptoms and enhance the quality of life, but also reduce the recurrence rate. Its mechanism may be regulating the level of brain-gut peptide, and then regulating the abnormal brain-gut axis, promoting gastrointestinal motility and reducing the visceral sensitivity in order to achieve therapeutic effect.%目的: 研究宣肺降浊方治疗便秘型肠易激综合征 ( IBS-C) 的临床疗效及可能作用机制.方法: 将120例患者随机分为2组: 治疗组60例予宣肺降浊方, 对照组60例予西沙比利.记录患者治疗前后临床症状、生存质量及治疗后复发情况.同时检测血浆神经肽Y (NPY)、 5-羟色胺 (5-HT)、血管活血肠肽 (VIP) 及降钙素基因相关肽 (CGRP) 含量.结果: 治疗组临床症状评分、总有效率、生存质量评分和复发率均优于对照组,差异有显著性 ( P <0.05).与本组治疗前比较, 治疗后患者血浆中5-HT、 NPY、 VIP、 CGRP含量降低, 差异有显著性 ( P <0.05).与对照组治疗后比较, 治疗组治疗后患者血浆中5-HT、 VIP、 NPY含量降低, 差异有显著性 ( P <0.05), 而CGRP含量升高, 但差异无显著性 ( P >0.05).结论: 宣肺降浊方不仅能够改善患者临床症状, 提高生活质量, 并且能够降低复发率, 其作用机制可能是通过调节脑肠肽的水平, 进而调控异常的脑-肠轴, 促进胃肠运动, 降低内脏的敏感性, 以达到治疗效果.
展开▼
